New Pharmaceutical Strategy for Europe – your input is requested!

Stella Kyriakides, European Commission commissioner for Health and Food Safety recently announced that “the Pharmaceutical Strategy for Europe is a cornerstone of our policy in the area of health for the next five years, and this is the chance for all stakeholders to help us shape it. “

Europe’s pharmaceutical sector is a major contributor to the EU economy in terms of creation of highly skilled jobs and investment in innovation, and now members of the public, healthcare professionals and providers, academia, researchers and the pharmaceutical industry are invited to contribute by completing an online questionnaire which will help guide the new Pharmaceutical Strategy for Europe

Coming in the wake of the COVID-19 pandemic, the strategy will also inform the newly proposed EU4Health Programme and align with Horizon Europe to create a “future proof” system which reaps the benefits of digitalisation and promotes innovation, especially in areas of unmet needs such as antimicrobials, medicines for children and medicines for rare diseases.

Find out more, and complete the questionnaire here.

Additional News

  • 7 August 2026

    Quinta-Analytica at CPHI Milan 2026 – Meet Us at Conscio Group Stand 6N25

    Meet Quinta-Analytica at CPHI Milan 2026 as part of the Conscio Group team at Stand 6N25. Discuss your clinical, bioanalytical and analytical projects with our experts and arrange a meeting in advance.

  • 15 July 2026

    Quinta-Analytica Awarded the EcoVadis Gold Medal

    Quinta-Analytica has been awarded the EcoVadis Gold Medal after achieving an overall sustainability score of 84 out of 100. The result represents a substantial increase from 68 points in the previous assessment and places the company in the 97th percentile globally.

  • 16 April 2026

    Expanding Beyond FDA & EMA: Strengthening Our Global Regulatory Footprint with GCC

    Quinta-Analytica has successfully completed a full on-site GCP inspection within the GCC framework, further strengthening its international regulatory footprint and clinical research credibility.